HOOK241220P5000
- 2.90
- 0.000.00%
HOOKIPA Pharma Newsroom
Hookipa Pharma Price Target Lowered to $7 From $24 at JMP Securities
Hookipa Pharma Announces Workforce Reduction of 80%, Pause of Eseba-vec Program
Sector Update: Health Care Stocks Climb Thursday Afternoon
HOOKIPA Pharma to Cut Workforce by 80%, Shift Focus to KRAS Cancer Program
JMP Securities Maintains HOOKIPA Pharma(HOOK.US) With Buy Rating, Cuts Target Price to $7
Strategic Shift and Partnership Potential Drive Buy Rating for HOOKIPA Pharma
Express News | HOOKIPA Pharma Inc: Will Focus Primarily on Progressing the Phase 1-Ready Hb-700 Program for the Treatment of Kras Mutant Cancers
Express News | HOOKIPA Pharma - Early Termination of Hpv16+ Trial Not Due to Efficacy or Safety
Express News | HOOKIPA Pharma - to Pause Clinical Development in Eseba-Vec Program
Express News | HOOKIPA Pharma - Restructuring Plan to Begin in Q4 2024, Complete by H1 2025
Express News | HOOKIPA Pharma Inc - on November 18, Co Approved a Planto Reduce Workforce by Approximately 80%
Analysts Are Bullish on These Healthcare Stocks: Hookipa Pharma (HOOK), Cue Biopharma (CUE)
Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky
HOOKIPA Pharma Is Maintained at Outperform by RBC Capital
HOOKIPA Pharma Analyst Ratings
HOOKIPA Pharma GAAP EPS of -$1.10 Beats by $0.18, Revenue of $4.7M Misses by $0.25M
Express News | HOOKIPA Pharma Inc : RBC Cuts Target Price to $48 From $50
Hookipa Pharma Reports Q3 Earnings Amid Strategic Changes
HOOKIPA Pharma | 10-Q: Q3 2024 Earnings Report
HOOKIPA Pharma | 8-K: HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates